Fungal prostatitis due to endemic mycoses and Cryptococcus: A multicenter case series

David J. Epstein MD1 | Lester D. R. Thompson MD2 | Atif Saleem DO3 | Chia-Sui Kao MD3 | Jonathan I. Epstein MD4

1Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California
2Department of Pathology, Southern California Permanente Medical Group, Pasadena, California
3Department of Pathology, Stanford University School of Medicine, Stanford, California
4Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland

Correspondence
David J. Epstein, MD, Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Lane Building, Mail Code 5107, Stanford, CA 94305. Email: depstein@stanford.edu

Abstract
Background: Fungal prostatitis is exceedingly rare with mostly case reports.
Methods: Electronic medical records at three medical centers were searched for cases of fungal prostatitis due to endemic mycoses and Cryptococcus over the preceding 10 years.
Results: Seven cases were identified from 105,600 prostate biopsies within the Southern California Permanente Medical Group for an incidence of 0.0066%. An additional eight cases were identified from two other health care systems. Excluding four patients without available clinical data, 11 patients were reviewed, most of whom underwent biopsy due to elevated prostate-specific antigen. Four were asymptomatic and the remainder had nonspecific signs or symptoms. All biopsies revealed granulomatous inflammation and fungal organisms. Seven patients had coccidioidomycosis, three patients had cryptococcosis (confirmed in two cases and suspected by organism morphology in the other), and one patient had likely histoplasmosis based on organism morphology. Prolonged antifungal treatment was standard; outcomes were favorable.
Conclusion: Fungal prostatitis due to endemic mycoses and Cryptococcus is uncommon and associated with favorable outcomes but generally involves prolonged therapy.

KEYWORDS
coccidioidomycosis, fungal prostatitis, fungi, mycoses, prostate cryptococcosis, prostate histoplasmosis, prostate infections

1 INTRODUCTION

While most diseases of the prostate are due to neoplasia or infection with typical bacterial pathogens (in the cases of acute or chronic bacterial prostatitis), fungi can also infect the prostate. Fungal prostatitis can be due to Candida species in the context of candidemia or an ascending urinary tract infection, but endemic mycoses, so named because of their geographic restriction, and Cryptococcus, a more widely distributed yeast, are underappreciated causes of infectious prostatitis. Endemic mycoses typically include species in the genera Coccidioides, Histoplasma, Blastomyces, and Paracoccidioides.

While Cryptococcus is not thermally dimorphic nor geographically restricted, it often causes similar clinical syndromes, including primary pulmonary infection with occasional extrapulmonary dissemination. Moreover, both Cryptococcus and endemic mycoses are often associated with characteristic epidemiologic risk factors.

Though case reports of fungal prostatitis due to endemic mycoses and Cryptococcus have been published, along with at least one small case series of prostatitis due to Coccidioides, to our knowledge there has no multicenter case series of these infections. Despite being relatively uncommon, these infections are often difficult to diagnose and may be associated with significant morbidity. We
report a case series of prostatitis due to endemic mycoses and Cryptococcus from three institutions.

2 MATERIAL AND METHODS

Our three institutions review large numbers of prostate biopsies annually. Two institutions (Stanford University School of Medicine and Johns Hopkins School of Medicine) are associated with large medical centers and review prostate biopsy specimens and slides from procedures performed locally as well as through consultative requests from regional and national health care systems. The third institution (Southern California Permanente Medical Group) is a large integrated health care organization with ~4.2 million members within Southern California. Seven of the cases were identified in a systematic review of 105,600 prostate specimens obtained from 2007 to 2017 within the Southern California Permanente Medical Group’s 12 medical centers, giving an incidence of 0.0066% of all patients with prostate biopsies. Institutional review board approval was obtained from each institution. Stanford IRB #47341; SCPMG IRB #11688; Johns Hopkins IRB #00184664. Electronic medical record systems were searched for cases within the past 10 years (beginning in 2007) with fungal prostatitis due to organisms from the genera Coccidioides, Histoplasma, Blastomyces, Paracoccidioides, Penicillium, and Cryptococcus. Infections due to Candida species and other non-Cryptococcus yeasts and molds with nonthermally dimorphic lifecycles (such as Aspergillus species) were excluded. Patients must have met established criteria for proven diagnosis with an endemic mycosis or cryptococcosis.

In addition to histopathologic features, patient information including demographics, clinical history, laboratory and microbiologic studies, imaging, treatment course, and outcome was collected. Patients whose clinical information was unable to be obtained were excluded. While histopathology can identify presence of fungal organisms and suggest the likely causative genus or species, histopathologic diagnosis is notoriously inaccurate and generally requires additional diagnostic testing or clinical input. Relevant microbiologic data included serologic assays (such as Coccidioides immunodiffusion and complement fixation titers, Histoplasma antigen or antibody assays, and cryptococcal antigen assays), fungal culture and phenotypic identification, and molecular identification. At one institution (Stanford Health Care), fungal identification by molecular sequencing is routinely employed in cases of suspected or proven fungal infection.

3 RESULTS

Out of 15 cases of prostatitis due to endemic mycoses and Cryptococcus, corresponding clinical information was available for 11 cases which were included in our analysis (Table 1). Of the remaining four patients without corresponding clinical data, three had organisms morphologically consistent with Coccidioides and one had an organism morphologically consistent with Cryptococcus. All specimens were obtained from core needle biopsies except for one specimen obtained via radical prostatectomy after an initial needle biopsy demonstrated carcinoma only without granulomatous inflammation or fungal organisms. The patients ranged in age from 43 to 79 years (median 57 years) and lived in California, Alabama, Arkansas, New Jersey, and Nebraska. The most common indication for prostate biopsy was elevated prostate-specific antigen (PSA). Four patients were entirely asymptomatic; the remaining patients had lower urinary tract symptoms, dysuria, hematuria, or testicular pain. With the exception of one patient with weight loss, fever, rigors, or other systemic complaints were absent. The results of physical examination and imaging (ultrasound or magnetic resonance imaging), when performed, were normal or nonspecific as to the cause of patients’ elevated PSA or symptoms. Among the nine patients with available white blood cell counts, none had leukocytosis. Among the five patients with erythrocyte sedimentation rate (ESR) and C-reactive protein studies available, all had normal values except for one patient with a slightly elevated ESR of 32 mm/h. Microscopic or dipstick urinalysis was available for nine patients and was normal in five; the remainder had either minimal pyuria (with no patient having more than 10 white blood cells per high-power field), glycosuria, or hematuria. Of the eight patients with available PSA results, seven had elevated PSA levels, with a median level of 13.0 ng/mL.

All biopsies revealed necrotizing or non-necrotizing granulomatous inflammation along with fungal organisms. Coccidioidomycosis was definitively diagnosed in seven patients, all of whom had histopathology results showing organisms consistent with Coccidioides as well as positive Coccidioides serologies (with complement fixation titers ranging from 1:4 to 1:32) (Figure 1). In one patient, the organism was identified by molecular sequencing. Two patients had confirmed cryptococcosis based on organism morphology and either positive serum cryptococcal antigen or growth of Cryptococcus from another body site (Figure 2). Two patients had confirmed fungal prostatitis though the organism could not be definitively identified, including one patient who was diagnosed with likely histoplasmosis based on compatible organism morphology though a histoplasma serum antibody was negative and another who was diagnosed with likely cryptococcosis though a serum cryptococcal antigen was negative. Adenocarcinoma was identified in three patients and atypical glands were identified in an additional three patients.

Three of the seven patients with coccidioidomycosis had a known history of this infection; all of these patients had either prior or concurrent pulmonary disease. One patient with coccidioidomycosis was African American; the others were White. All patients with coccidioidomycosis lived in California, except for one who lived in the Midwestern United States at the time of the diagnosis but had lived in California for many years earlier in his life. On review of medical records, this patient presented with fevers and consolidations on chest radiography many years before when he lived in California; coccidioidomycosis commonly presents as community-acquired pneumonia and is often undiagnosed. Another patient with coccidioidomycosis had involvement of the testicle and underwent an orchietomy. Diabetes mellitus was present in three of the patients.
<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Significant history or comorbidities</th>
<th>Presenting signs and symptoms</th>
<th>Histopathology</th>
<th>Adenocarcinoma or atypia</th>
<th>Microbiologic data</th>
<th>Treatment and outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Coccidioidomycosis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>None</td>
<td>Elevated PSA; asymptomatic; prior needle biopsy with carcinoma</td>
<td>Prostatectomy specimen; necrotizing granulomas; spherules consistent with Coccidioides</td>
<td>Adenocarcinoma; 3 + 3 = 6</td>
<td>Molecular sequencing identified Coccidioides; Coccidioides CF 1:8 and 1:32 on repeat</td>
<td>Fluconazole for several months; prolonged follow-up not available</td>
</tr>
<tr>
<td>64</td>
<td>History of pulmonary coccidioidomycosis 5 y prior</td>
<td>Elevated PSA; LUTS; mild pyuria</td>
<td>Granulomatous and mixed inflammation; spherules consistent with Coccidioides</td>
<td>None</td>
<td>Coccidioides CF 1:32</td>
<td>Fluconazole for 5 y</td>
</tr>
<tr>
<td>52</td>
<td>DM; CKD; substance-use disorder</td>
<td>Elevated PSA; intermittent hematuria</td>
<td>Acute and chronic inflammation and noncaseating granulomas; spherules consistent with Coccidioides</td>
<td>Few atypical glands consistent with atypical small acinar proliferation</td>
<td>Coccidioides CF 1:8</td>
<td>Fluconazole for 2 y</td>
</tr>
<tr>
<td>72</td>
<td>None</td>
<td>Elevated PSA; asymptomatic</td>
<td>Non-necrotizing granulomas; spherule consistent with Coccidioides</td>
<td>Adenocarcinoma; 3 + 3 = 6</td>
<td>Coccidioides CF 1:32</td>
<td>Fluconazole for 9 y</td>
</tr>
<tr>
<td>43</td>
<td>History of pulmonary coccidioidomycosis 6 y prior; substance-use disorder and alcoholism</td>
<td>Elevated PSA; asymptomatic</td>
<td>Acute and chronic inflammation; spherules with endospores consistent with Coccidioides</td>
<td>None</td>
<td>Coccidioides CF 1:16</td>
<td>Fluconazole for 11 mo</td>
</tr>
<tr>
<td>79</td>
<td>DM; CKD; Alzheimer’s disease</td>
<td>Elevated PSA; asymptomatic</td>
<td>Non-necrotizing granulomas; spherules consistent with Coccidioides</td>
<td>None</td>
<td>Coccidioides CF 1:4</td>
<td>Fluconazole for ≥8 mo; orchiectomy for testicular Coccidioides involvement</td>
</tr>
<tr>
<td>58</td>
<td>History of pulmonary coccidioidomycosis 5 y prior; DM; CKD; cardiomyopathy; obesity</td>
<td>Elevated PSA; LUTS; mild pyuria</td>
<td>Non-necrotizing and necrotizing granulomas; spherules with endospores consistent with Coccidioides</td>
<td>Adenocarcinoma; 3 + 3 = 6</td>
<td>Coccidioides CF 1:4</td>
<td>Fluconazole for 11 mo</td>
</tr>
<tr>
<td><strong>Cryptococcosis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>History of kidney transplant 18 y prior (on azathioprine and prednisone)</td>
<td>Elevated PSA; LUTS; glycosuria and hematuria</td>
<td>Granulomas; fungal organisms consistent with Cryptococcus</td>
<td>None</td>
<td>Cryptococcus identified in CSF</td>
<td>Unknown</td>
</tr>
<tr>
<td>57</td>
<td>Rheumatoid arthritis on methotrexate and infliximab; recurrent herpes zoster</td>
<td>Elevated PSA; dysuria</td>
<td>Granulomas; fungal organisms consistent with Cryptococcus</td>
<td>Small focus of atypical glands highly suspicious for carcinoma</td>
<td>Serum cryptococcal antigen 1.8</td>
<td>Fluconazole for 2 mo</td>
</tr>
<tr>
<td>47</td>
<td>HIV with T-lymphocytes of 350 cells/µL on antiretroviral therapy; history of cryptococcal meningitis 4 y prior</td>
<td>LUTS; weight loss; hematuria</td>
<td>Fungal organisms with capsule stain likely Cryptococcus</td>
<td>None</td>
<td>Serum cryptococcal antigen negative</td>
<td>Fluconazole for ≥3 y</td>
</tr>
</tbody>
</table>
with coccidioidomycosis; other comorbidities present in more than one patient included chronic kidney disease and alcoholism or substance-use disorder.

All three patients with cryptococcosis were immunocompromised: one was status post renal transplantation and remained on immunosuppression; another was being treated with infliximab and other medications for rheumatoid arthritis; and the third patient had human immunodeficiency virus (HIV) infection with a T-lymphocyte count of ~350 cells/μL while on antiretroviral therapy. The renal transplant patient had concomitant cryptococcal meningitis and the patient with HIV had cryptococcal meningitis approximately 4 years earlier. The patient with presumed histoplasmosis was healthy, although he lived in an area of moderate to high *Histoplasma* endemicity.

Patients with coccidioidomycosis were generally treated with fluconazole for durations ranging from several months to several years. Itraconazole or fluconazole was used to treat patients with presumed histoplasmosis or cryptococcosis, generally for shorter durations. Outcomes were generally favorable though some patients remain on treatment at the time of data collection. No patient deaths were identified.

### 4 | DISCUSSION

No case series of fungal prostatitis due to endemic mycoses and *Cryptococcus* have been published to our knowledge in over a decade. Two prior case series published in 2005 and 2006 focused exclusively on coccidioidomycosis and were both single-center studies from Arizona.2,6 One case series identified four patients with prostatitis due to *Coccidioides* out of 3676 specimens between 1994 and 2000, yielding an incidence of 0.11% during this period or 0.02% per year.2 Two patients were untreated and reportedly did well and two other patients were treated (though one died of disseminated coccidioidomycosis despite aggressive antifungal therapy).2 The other case series also identified four patients with *Coccidioides* prostatitis (in addition to other patients with nonprostatic genitourinary *Coccidioides* infections).6 As in our study, pulmonary coccidioidomycosis was sometimes seen as well and patients presented with indolent disease and were often asymptomatic; one patient was monitored without treatment.6 A recent case report and literature review found 70 reported cases of prostatic cryptococcosis since the 1940s, also mostly in immunocompromised patients with frequent dissemination.7 Prostatic blastomycosis and para-coccidioidomycosis have been reported only rarely.8–10

*Coccidioides, Histoplasma,* and *Cryptococcus* were identified as etiologic agents of fungal prostatitis in this multicenter case series. As evidenced by patients’ clinical presentations, these infections are impressively indolent. Leukocytosis, elevations in inflammatory markers, or pyuria, typical markers of systemic, or genitourinary tract infection, were often absent or muted. In fact, most of these infections were discovered incidentally during biopsies for patients with elevated PSA being evaluated for malignancy. Most patients had no concurrent extraprostatic loci of infection though some had prior known fungal infections. Coccidioidomycosis was particularly common in our case series, perhaps reflecting that two of the three centers in this study were in California, and

<table>
<thead>
<tr>
<th>Age (y)</th>
<th>Significant history or comorbidities</th>
<th>Presenting signs and symptoms</th>
<th>Histopathology</th>
<th>Adenocarcinoma or atypia</th>
<th>Microbiologic data</th>
<th>Treatment and outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>61</td>
<td>None</td>
<td>Testicular pain, BPH</td>
<td>Granulomas; intracellular budding yeast consistent with <em>Histoplasma</em></td>
<td>Small focus of atypical glands suspicious for carcinoma</td>
<td>Histoplasma antibody negative</td>
<td>Histoplasma antibody negative; Itraconazole for 3 mo</td>
</tr>
<tr>
<td>62</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None; Itraconazole for 6 mo</td>
</tr>
</tbody>
</table>

Abbreviations: BPH, benign prostatic hyperplasia; CF, complement fixation; CKD, chronic kidney disease; DM, diabetes mellitus; HIV, human immunodeficiency virus; LUTS, lower urinary tract symptoms; PSA, prostate-specific antigen.
**FIGURE 1** Necrotizing granulomas on prostate needle biopsy (A) with higher magnification (B) showing mature spherules with outer thick wall and numerous endospores. Another case showing non-necrotizing granulomas adjacent to intact prostate glands (C). Higher magnification (D) shows a single spherule [Color figure can be viewed at wileyonlinelibrary.com]

**FIGURE 2** Granulomatous prostatitis with numerous multinucleated histiocytes containing pale vacuoles with suggestion of features suspicious for *Cryptococcus* (A). Gomori Methenamine-Silver (GMS) stain shows numerous cryptococcal forms (B) in histiocytes. Prostate with necrosis (right) (C). GMS stain shows numerous cryptococcal forms (D) in tissue [Color figure can be viewed at wileyonlinelibrary.com]
affect patients who were generally healthy. That our calculated incidence of coccidioidomycosis from Southern California was substantially lower than calculated by the aforementioned Arizona-based study may reflect differences in regional epidemiology. While those of African or Filipino descent are thought to be at higher risk of disseminated coccidioidomycosis, most of the patients in this series with prostatitis due to Coccidioides were White. Unlike those with coccidioidomycosis, all patients with cryptococcal prostatitis in our case series had profoundly impaired cellular immunity due to HIV infection, solid organ transplantation, or use of anti-inflammatory monoclonal antibody drugs, suggesting that disseminated infections due Cryptococcus are more likely in immunocompromised patients. Relatively prolonged treatment with systemic antifungals led to generally favorable outcomes.

Ours is the only comprehensive case series of patients with fungal prostatitis due to endemic mycoses and Cryptococcus to our knowledge, and includes a diversity of institutions, including a large integrated health care organization and two referral medical centers. While histoplasmosis and coccidioidomycosis are nationally notifiable conditions, others (such as blastomycosis, cryptococcosis—except infections due to C. gattii—and paracoccidioidomycosis) are not. Given these limited data, case series such as ours are critical in discerning the presentation, diagnostic methods, and treatment patterns for these infections. As a case series, our data cannot be used to calculate the incidence of fungal prostatitis due to these mycoses. Moreover, the distribution of particular fungal etiologies may reflect a sampling bias, particularly since two of our three institutions are in California and since certain consultative requests may not be made equally for all types of fungal prostatitis. Finally, in two cases, definitive identification of the fungal genus or species could not be made given negative serologic evaluation.

Given an apparent increase in coccidioidomycosis in the American West and Southwest, cases of fungal prostatitis due to Coccidioides may increase as well. Moreover, while new cases of HIV are declining, the array of potent immunosuppressive drugs for malignant and autoimmune conditions continues to grow, which may place patients at increased risk of disseminated cryptococcosis and other infections. As cryptococcosis and infections due to endemic mycoses are often multi-system diseases with hematogenous dissemination, providers should carefully evaluate patients for disease involvement outside the genitourinary tract.

5 CONCLUSIONS

Fungal prostatitis due to endemic mycoses and Cryptococcus is uncommon but has important clinical implications. Prostatic coccidioidomycosis and histoplasmosis can occur in otherwise healthy individuals though prostatitis due to Cryptococcus is likely more common among patients with profoundly compromised immunity. Patients often present asymptptomatically or with minimal symptoms; classic signs and symptoms of infection are uncommon and laboratory studies and imaging are often normal or unimpressive. Treatment with prolonged antifungal therapy is associated with favorable outcomes.

CONFLICT OF INTERESTS

All the authors declare that there are no conflict of interests.

ORCID

David J. Epstein https://orcid.org/0000-0002-8541-2623
Jonathan I. Epstein https://orcid.org/0000-0003-1839-6472

REFERENCES


How to cite this article: Epstein DJ, Thompson LDR, Saleem A, Kao C-S, Epstein JI. Fungal prostatitis due to endemic mycoses and Cryptococcus: A multicenter case series. The Prostate. 2020;80:1006–1011. https://doi.org/10.1002/pros.24034